Probi
347
SEK
0 %
PROB
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Vær den første som følger denne virksomhed
0%
+24,82%
+37,15%
+62,15%
+70,94%
+75,7%
-21,49%
+50,54%
+3.134,72%
www.probi.com/investor-relations
Probi is a biotechnology company. The company is particularly focused on the research and development of probiotics, a bacterium that is found in the human intestinal system. The research areas within the company include the gastrointestinal, immune system, metabolic syndrome, and stress and recovery. The company's customers include larger corporate customers active in the food industry. The company was founded in 1991 and is headquartered in Lund.
Omsætning
627,69 mio.
EBIT %
1,8 %
P/E
234,46
Udbytteafkast, %
0,37 %
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
PROB
Daglig lav / høj pris
347 / 349
SEK
Markedsværdi
3,95 mia. SEK
Aktieomsætning
266,93 t SEK
Volumen
768
Seneste videoer
Finanskalender
Årsrapport
28.01.2025
Delårsrapport
23.04.2025
Generalforsamling
06.05.2025
Delårsrapport
17.07.2025
Delårsrapport
23.10.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Symrise | 69,7 % | 69,7 % |
Fjärde AP-fonden | 9,3 % | 9,3 % |
Caceis Bank | 8,3 % | 8,3 % |
Avanza Pension | 0,6 % | 0,6 % |
The Bank of New York Mellon, W9 | 0,5 % | 0,5 % |
J.P.Morgan SE, Luxembourg Branch, W8IMY/NQI | 0,5 % | 0,5 % |
Nordnet Pensionsförsäkring AB | 0,3 % | 0,3 % |
Österlin, Claes | 0,3 % | 0,3 % |
SEB Sverige Indexnara | 0,3 % | 0,3 % |
ViserAlle indholdstyper
Probi CFO departure
Probi Launches Clinically-Supported Probiotic Solution for Metabolic Health at SupplySide West 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools